Related Experiment Video
Updated: Mar 31, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Incorporation of clinical and molecular variant properties improves the performance of in silico pathogenicity
Ofer Isakov1, Reut Fluss2, Dina Marek-Yagel2
1Raphael Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel; Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel; The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration, Harvard Medical School and Clalit Research Institute, Boston, MA; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Purpose:
In silico pathogenicity prediction tools performance can vary depending on molecular and clinical contexts. This study aims to assess the performance of commonly used tools under different conditions. Additionally, the study aims to recalibrate score thresholds to better reflect evidence of pathogenicity.
Methods:
ClinVar variants were stratified by allele frequency, conservation, mode of inheritance, and disease category. For each subset, Bayesian methods were used to recalibrate thresholds corresponding to the levels of evidence defined by the American College of Medical Genetics.
Results:
Tools exhibited reduced accuracy for variants with higher allele frequencies and for variants located in regions with high conservation. Variants affecting autosomal recessive and X-linked genes were more accurately classified compared with those affecting autosomal dominant genes. Recalibrated thresholds consistently showed higher odds of correctly estimating pathogenicity (OR=3.78 [1.74, 8.55]; P < .001) and produced significantly higher scores for known pathogenic variants and lower scores for benign/likely benign. This improved discriminatory performance was particularly notable in variants found in low-conservation regions and autosomal recessive genes.
Conclusion:
Pathogenicity prediction tools should be evaluated using various variant subsets during development. Score threshold recalibration extends the range of evidence and improves overall pathogenicity probability estimation and classification.
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Single Nucleotide Polymorphisms-SNPs
In-vitro Mutagenesis
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu